EGFR and non-small cell lung carcinoma: In patients with EGFR mutated oligometastatic NSCLC, systemic therapy with third line EGFR inhibitor such as osimertinib represents the “gold standard” achieving very favorable results in terms of clinic outcomes when compared with CHT.